Blue Sky MD review
Blue Sky MD is a physician-led medical weight-loss practice (founded 2008, LegitScript-certified, Medical Director Dr. David LaMond) with 7 physical clinics across North Carolina.
- Semaglutide
- $160/mo (starting dose, compounded)
- Tirzepatide
- $240/mo (starting dose, compounded)
- Coverage
- 1 state
- Brand-name
- Compounded only
Semaglutide · modeled / year
$1,920
Tirzepatide · modeled / year
$2,880
Pricing verified August 2026
The Index scorecard
Blue Sky MD scored on our six Cost-Efficiency Index factors. See the methodology.
Where the value is
- LegitScript-certified with a named, pictured Medical Director (Dr. David LaMond) and a practice history dating to 2008
- Weekly pricing ($40 semaglutide / $60 tirzepatide) is well below brand-name cost and comparable to many compounded telehealth competitors
- 7 physical clinic locations across North Carolina (Charlotte, Asheville, Hendersonville, Greensboro, Clemmons, South Charlotte, Mooresville) for patients who want in-person care
- Comprehensive program includes wellness coaching, nutrition plans, and hormone analysis alongside medication
The tradeoffs
- The published $40/$60 per-week price is explicitly labeled 'in-office' on the GLP-1 page, and that specific page never mentions telehealth at all — whether the rate applies to out-of-state or telehealth-only patients is unconfirmed
- Geographic footprint is North Carolina only; no state-by-state telehealth coverage list is published
- No compounding pharmacy is named anywhere on the site
- Pricing is quoted per-week rather than per-month, and no higher-dose pricing is disclosed
The bottom line
Best for: Cost-first shoppers who want north Carolina residents who want an established, physician-led, LegitScript-certified in-person clinic. Blue Sky MD is a physician-led medical weight-loss practice (founded 2008, LegitScript-certified, Medical Director Dr. David LaMond) with 7 physical clinics across North Carolina.
Ranked #188 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.
Compare with other providers
All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Blue Sky MD.
- #168RestorLife Med— RestorLife Med is a physician-guided GLP-1 telehealth practice.65/100
- #169SnagRx— SnagRx is a telehealth platform offering compounded semaglutide and tirzepatide with unusually specific named pharmacy partners (RedRock, Health Warehouse, Precision Compounding, Triad Rx) and a claimed LegitScript certification.65/100
- #170Teleios Health— Teleios Health markets itself as a physician-led GLP-1 telehealth provider offering both compounded semaglutide and tirzepatide.65/100
- #171YourEra— Two molecules, two headline prices, and two different reasons neither headline is what you will actually be billed in month two.62/100
- #172Levity— Levity is a telehealth weight-loss provider dispensing only FDA-approved branded GLP-1 medications Ozempic ($1,199/mo), Mounjaro ($1,299/mo) and Wegovy ($1,599/mo), all all-inclusive of consultation, prescription and shipping.64/100
- #173AlyveRx— AlyveRx (Alyve) is a telehealth platform selling compounded semaglutide and tirzepatide in both standard injection and proprietary PermeAct sublingual-drop form, plus brand Ozempic, Wegovy.64/100
The 24 programs nearest this one
- #189 CaliberRx63
- #190 Calibrate Health63
- #191 CoraDoc63
- #192 Curve63
- #193 Green Cap Health63
- #194 iThriveMD63
- #195 Lavender Sky Health63
- #196 LillyDirect Foundayo63
- #197 LunaRx63
- #198 Next Vial63
- #199 Peptivo63
- #200 Semaglutide Online63
- #201 VitaStir63
- #202 Wisp63
- #203 MEDGm60
- #204 Allara Health62
- #205 Care Clinics62
- #206 ElitePhysiqMD62
- #207 GobyMeds62
- #208 Livea62
- #209 OnlineSemaglutide.org62
- #210 OurView Health62
- #211 ReadyRx62
- #212 Somi Health62
Pricing, states and verification reflect Blue Sky MD's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Blue Sky MD's site. Not medical advice; see our disclosure.